Anti Cancer Tablets

Approx. Rs 3,500 / BoxGet Latest Price

Product Details:

Erlotero 100mg Tablet is used in the treatment of non-small cell lung cancer and pancreatic cancer.

Erlotero 100mg Tablet should be taken on an empty stomach or should be taken one hour before or 2 hour after meal.  You should continue to take it as long as your doctor advises it. The duration of treatment varies according to your needs and response to treatment. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.

The most common side effects of this medicine include nausea, vomiting, fatigue, rash, and weight loss. It may cause severe diarrhea, drink plenty of fluids or consult with your doctor if it bothers you. It makes you sensitive towards sunlight, hence wear protective clothing or use sunscreen while going out. In case you develop ulceration in mouth, changes in your vision, or breathing difficulties than it is better to inform the doctor. Your doctor may advise for regular monitoring of liver function while you are taking this medicine.

Approx. Rs 30,500 / BoxGet Latest Price

Product Details:

Kryxana Ribociclib 200mg Tablet is used in the treatment of metastatic breast cancer. It helps to slow down the growth of cancer cells and eventually kills them.

Kryxana 200mg Tablet is taken in a dose as advised by the doctor. The duration of treatment varies on the basis of your need and response to treatment. You may be asked for regular blood tests while taking this medication. It is better to inform doctor if you notice symptoms of infection like fever, chills and weakness. You should use effective contraception method to prevent pregnancy while taking this medicine

It may cause dizziness, so avoid driving or any activity requiring mental focus until you know how it affects you. Neutropenia is a well-recognized adverse effect, in which the number of your white blood cells get reduced and your immune system gets weakened. As a result, you may be at greater risk of getting an infection. However, this side effect disappears rapidly once you stop taking the medicine.

Quick Tips

• Take it with food, preferably at the same time every day. 
• If you forget to take the medicine or vomit, skip the missed dose and follow a regular schedule. Do not take a double dose to make up missed dose
• Use effective contraception method to prevent pregnancy while taking this medicine.
• It may cause dizziness. Avoid driving or any activity requiring mental focus until you know how it affects you.
• You may be asked for regular blood tests while taking this medication. Inform your doctor if you notice symptoms of infection like fever, chills, and weakness.
• Inform your doctor if you are pregnant, planning pregnancy or breastfeeding.
• Do not stop taking the medication without talking to your doctor first.

Approx. Rs 4,500 / BoxGet Latest Price

Product Details:

Erlotinib 150 that is primarily used for treating cell lung cancer. Furthermore, it treats pancreatic cancer when consumed in combination with a certain other medicine. This effective and precisely composed medication works by inhibiting growth to adjacent tissues in the body. Erlotinib 150 tablets are provided in moisture-proof packaging.

Note :- Erlonat Is A Prescription Drug And Should Be Used Under Proper Medical Guidance And Advice. Do Not Share The Medicine With Others, Since They May Be Suffering From A Problem That Is Not Effectively Treated By This Drug.

Approx. Rs 3,800 / BoxGet Latest Price

Product Details:

Erlotinib is an epidermal growth factor receptor/human epidermal growth factor receptor type 1 (EGFR, also known as HER1) tyrosine kinase inhibitor. Erlotinib potently inhibits the intracellular phosphorylation of EGFR. EGFR is expressed on the cell surface of normal cells and cancer cells. In non-clinical models, inhibition of EGFR phosphotyrosine results in cell stasis and/or death. Specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized.

EGFR mutations may lead to constitutive activation of anti-apoptotic and proliferation signalling pathways. The potent effectiveness of erlotinib in blocking EGFR-mediated signalling in these EGFR mutation-positive tumours is attributed to the tight binding of erlotinib to the ATP-binding site in the mutated kinase domain of the EGFR. Due to the blocking of downstream signalling, the proliferation of cells is stopped and cell death is induced through the intrinsic apoptotic pathway. Tumour regression is observed in mouse models of enforced expression of these EGFR-activating mutations.

Absorption and Distribution

• Erlotinib is about 60% absorbed after oral administration and its bioavailability is substantially increased by food to almost 100%. Peak plasma levels occur 4 hours after dosing. The solubility of erlotinib is pH-dependent. Erlotinib solubility decreases as the pH increases. Co-administration of erlotinib with omeprazole, a proton-pump inhibitor, decreased the erlotinib exposure (AUC) and maximum concentration (Cmax) by 46% and 61%, respectively. When erlotinib was administered 2 hours following a 300 mg dose of ranitidine, an H2-receptor antagonist, the erlotinib AUC was reduced by 33% and the Cmax by 54%. When erlotinib was administered with ranitidine 150 mg twice daily (at least 10 hours after the previous ranitidine evening dose and 2 hours before the ranitidine morning dose), the erlotinib AUC and Cmax decreased by 15% and 17%, respectively.
• Following absorption, erlotinib is approximately 93% protein-bound to plasma albumin and alpha-1 acid glycoprotein (AAG). Erlotinib has an apparent volume of distribution of 232 litres.

Metabolism and Excretion

 

• A population pharmacokinetics analysis in 591 patients receiving a single-agent erlotinib 2nd/3rd line regimen showed a mean apparent clearance of 4.47 l/hour, with a median half-life of 36.2 hours. Time to reach steady-state plasma concentration would, therefore, be 7–8 days. No significant relationships of clearance to covariates of patient age, body weight or gender were observed. Smokers had a 24% higher rate of erlotinib clearance.

Approx. Rs 3,000 / BoxGet Latest Price

Product Details:

Established in the year 2019 at Delhi, Maharashtra, we “Wellcome Health Care” are a Proprietor based firm, engaged as the foremost Wholesale Trader and manufacturer of Anti Cancer Medicine, HIV Infection Medicine, Pharma Injection, Antiviral Tablets, Capecitabine Tablets, Entecavir Tablets, and much more. Our products are high in demand due to their premium quality, seamless finish, different patterns and affordable prices. Furthermore, we ensure to timely deliver these products to our clients, through this we have gained a huge clients base in the market

Approx. Rs 200 / BoxGet Latest Price

Product Details:

Ablu 50mg Tablet is used in the treatment of cancer of the prostate gland. It may be also used to treat other conditions, as determined by the doctor. It works by blocking the effects of male hormones such as testosterone.

Approx. Rs 40,000 / BoxGet Latest Price

Product Details:

Bdenza 40mg Capsule is used in the treatment of cancer of the prostate gland. It may be also used to treat other conditions, as determined by the doctor. It works by blocking the effects of male hormones such as testosterone

Approx. Rs 4,000 / BoxGet Latest Price

Product Details:

Erlotinib is an epidermal growth factor receptor/human epidermal growth factor receptor type 1 (EGFR, also known as HER1) tyrosine kinase inhibitor. Erlotinib potently inhibits the intracellular phosphorylation of EGFR. EGFR is expressed on the cell surface of normal cells and cancer cells. In non-clinical models, inhibition of EGFR phosphotyrosine results in cell stasis and/or death. Specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized.

EGFR mutations may lead to constitutive activation of anti-apoptotic and proliferation signalling pathways. The potent effectiveness of erlotinib in blocking EGFR-mediated signalling in these EGFR mutation-positive tumours is attributed to the tight binding of erlotinib to the ATP-binding site in the mutated kinase domain of the EGFR. Due to the blocking of downstream signalling, the proliferation of cells is stopped and cell death is induced through the intrinsic apoptotic pathway. Tumour regression is observed in mouse models of enforced expression of these EGFR-activating mutations.

Absorption and Distribution

• Erlotinib is about 60% absorbed after oral administration and its bioavailability is substantially increased by food to almost 100%. Peak plasma levels occur 4 hours after dosing. The solubility of erlotinib is pH-dependent. Erlotinib solubility decreases as the pH increases. Co-administration of erlotinib with omeprazole, a proton-pump inhibitor, decreased the erlotinib exposure (AUC) and maximum concentration (Cmax) by 46% and 61%, respectively. When erlotinib was administered 2 hours following a 300 mg dose of ranitidine, an H2-receptor antagonist, the erlotinib AUC was reduced by 33% and the Cmax by 54%. When erlotinib was administered with ranitidine 150 mg twice daily (at least 10 hours after the previous ranitidine evening dose and 2 hours before the ranitidine morning dose), the erlotinib AUC and Cmax decreased by 15% and 17%, respectively.
• Following absorption, erlotinib is approximately 93% protein-bound to plasma albumin and alpha-1 acid glycoprotein (AAG). Erlotinib has an apparent volume of distribution of 232 litres.

Metabolism and Excretion

 

• A population pharmacokinetics analysis in 591 patients receiving a single-agent erlotinib 2nd/3rd line regimen showed a mean apparent clearance of 4.47 l/hour, with a median half-life of 36.2 hours. Time to reach steady-state plasma concentration would, therefore, be 7–8 days. No significant relationships of clearance to covariates of patient age, body weight or gender were observed. Smokers had a 24% higher rate of erlotinib clearance.

Approx. Rs 400 / BoxGet Latest Price

Product Details:

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Side Effects

• Hot flashes, headache, trouble sleeping, dizziness, stomach upset, nausea/vomiting, constipation, diarrhea, loss of appetite, weight gain, tiredness/weakness, increased coughing, or sore throat may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.
• Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Approx. Rs 1,300 / BoxGet Latest Price

Product Details:

The mechanism of the clinical antitumour action of gefitinib is not fully characterized. Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinases associated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK).

The epidermal growth factor (EGF) and its receptor (EGFR ) have been identified as key drivers in the process of cell growth and proliferation for normal and cancer cells. EGFR activating mutation within a cancer cell is an important factor in promotion of tumour cell growth, blocking of apoptosis, increasing the production of angiogenic factors and facilitating the processes of metastasis.

Gefitinib is a selective small molecule inhibitor of the epidermal growth factor receptor tyrosine kinase and is an effective treatment for patients with tumours with activating mutations of the EGFR tyrosine kinase domain regardless of line of therapy. No clinically relevant activity has been shown in patients with known EGFR mutation-negative tumours.

Approx. Rs 2,500 / BoxGet Latest Price

Product Details:

Endace 160 Tablet is used to treat breast cancer and endometrial cancer. It specifically helps treat breast and endometrial cancer that are hormone dependent. It may also be used for treating low appetite and weight loss in patients with advanced cancer or HIV.


Endace 160 Tablet should be taken with or without food, preferably at a fixed time each day to ensure consistent levels of medicine in the body. This medicine is not used for pregnant or breastfeeding women. It may cause side effects like high blood pressure and increased blood sugar levels but they are temporary. However, if these persist, consult with the doctor.

Side effectsMajor & minor side effects for Endace-160 Tablet

• Sleeplessness
• Rash
• Sweating
• Diarrhea
• Indigestion
• Mood swings
• Weight gain
• Nausea
• Vomiting
• Increase in blood pressure
• Increased thirst

Approx. Rs 300 / BoxGet Latest Price

Product Details:

We can supply and export Erlotinib Tablets at reasonable rates in bu;lk quantity. These are available in ready stock.